Loading…

Publications

Kandula T, Farrar MA, Kiernan MC, Krishnan AV, Goldstein D, Horvath L, Grimison P, Boyle F, Baron-Hay S, Park SB (2017). Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clin Neurophysiol. 128(7):1166-1175.

Lees JG, Makker PG, Tonkin RS, Abdulla M, Park SB, Goldstein D, Moalem-Taylor G (2017). Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer. 73:22-29.

Makker PG, Duffy SS, Lees JG, Perera CJ, Tonkin RS, Botovsky O, Park SB, Goldstein D, Moalem-Taylor G (2017). Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLOS One. 12(1): e0170814.

Kandula T, Park SB, Cohn RJ, Farrar MA. (2016) Pediatric chemotherapy induced peripheral neuropathy: a systematic review of current knowledge. Cancer Treatment Reviews. 50: 118-128.

Krishnan AV, Park SB. (2014). Chemotherapy-induced peripheral neuropathy: the end of the beginning? Journal of Neurology, Neurosurgery and Psychiatry. 85:359. Invited commentary PMID: 23833264

Park SB, Kwok JB, Loy CT, Friedlander ML, Lin CS, Krishnan AV, Lewis CR, Kiernan MC. (2014). Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer. 22;14:993. doi: 10.1186/1471-2407-14-993.

Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA A Cancer Journal for Clinicians. 63:419-437 PMID: 24590861

Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer. 20(11):2959-67. PMID: 22426503

Park SB, Koltzenburg M, Lin CS, Kiernan MC. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 78(2): 152. PMID: 22232054

Park SB, Lin CS, Kiernan MC. (2012) Nerve excitability assessment in chemotherapy-induced neurotoxicity. Journal of Visualized Experiments 62: 3439. PMID: 22565594

Park SB, Goldstein D, Lin CSY, Krishnan AV, Friedlander ML & Kiernan MC (2011) Neuroprotection for Oxaliplatin-induced neurotoxicity: What happened to objective assessment? Journal of Clinical Oncology.29 (18): e553-554. PMID: 21606425

Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC (2011) Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of Neurotoxicity. PLoS ONE 6(4): e18469. PMID: 21494615

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC (2011) Long-term Neuropathy after Oxaliplatin Treatment: Challenging the Dictum of Reversibility? The Oncologist.16: 708-716. PMID: 21478275

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, & Kiernan MC. (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology. 227(1): 120-127. PMID: 20965170

Park SB, Lin CS, Krishnan AV & Kiernan MC (2011) The contributions of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: Direct or indirect effects? Cancer, Chemotherapy, and Pharmcology 67(5):1189-1190. PMID: 21327679

Park SB, Lin CS, Krishnan AV, Lewis CR, Friedlander ML, & Kiernan MC. (2011) Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve. 43(3): 367-374 PMID: 21321953

Park SB, Goldstein D, Lin CSY, Krishnan AV, Friedlander ML & Kiernan MC. (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology27 (8): 1243-1249. PMID: 19164207

Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC. (2009) Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction. Oncology 77:342 – 348. PMID: 20016227

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132: 2712-2723. PMID: 19745023

Krishnan AV, Lin CS, Park SB & Kiernan MC. (2008) Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System 13(1): 7-26.

Park SB, Krishnan AV, Lin CSY, Goldstein D, Friedlander ML & Kiernan MC. (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current Medicinal Chemistry 15(29):3081 – 3094. Invited Review

Kiernan MC. (2007) The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer. 43(18):2631-3.

Kiernan MC, Krishnan AV. (2006) The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem. 13(24):2901-7.

Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. (2006). Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res. 1;12(15):4481-4.

Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer. 6(2):146-51.

Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. (2005). Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 32(1):51-60.